Media contact: Hannah Echols, echolsh@uab.edu
David Geldmacher, M.D.
Division of Memory Disorders
Areas of expertise:
- Memory disorders
- Alzheimer’s disease
- Dementia
- Clinical trials of dementia therapy
- Dementia risk assessment
- Visual processing
Geldmacher is an international figure in memory disorders, dementia, Alzheimer’s disease and mild cognitive impairment.
He created the UAB Alzheimer’s Risk Assessment and Intervention Clinic, the first such clinical service in the nation. Patients receive a detailed, personalized risk assessment, which includes family history, a detailed memory history, cognitive testing and a baseline MRI scan. That information is incorporated into existing risk-predictor models, which have been validated by research studies that followed thousands of patients for as many as 20 years to produce an accurate risk assessment.
He is a Fellow of the American College of Physicians and a member of the American Academy of Neurology and the American Neurological Association.
Media Apperances:
-
FDA Approves Groundbreaking Alzheimer's Drug- Birmingham Medical News
-
Alzheimer’s drug with ability to slow down disease gets full FDA approval- WBRC
-
New therapy offers hope in fight against Alzheimer's Disease- WVTM
-
Alzheimer’s support organizations in Alabama react to approval of new treatment drug- CBS 42
-
Can the MIND Diet Slow the Progression of Alzheimer's?- Discover Magazine
-
New data shows Alzheimer’s affects on Alabama at a county-by-county level- WBRC